Clinical Trial Update: Phase Ib Clinical Study of HDM1005 Injection [Phase 1]

View source ↗

Summary

This document notes the completion of the Phase 1 portion of a Phase Ib study of the HDM1005 injection for overweight and obesity.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Overweight

Drugs mentioned

• HDM1005

Snippet

Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Conditions: Overweight and Obesity | Phase 1 | Status: COMPLETED